Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Apr 28, 2023 7:20pm
233 Views
Post# 35420319

RE:RE:Let me try again.....

RE:RE:Let me try again.....
Rumpl3StiltSkin wrote: Fred, I don't think it matters as I believe they are using the correct and full data to apply for BTD and AA. If they have some new way of presenting the data moving forward? I guess as long as the FDA and other regulators are ok with it why not? At least it eliminates the 12 undertreated. That doesn't mean they didnt mess up the swimmers plot. It is very confusing to me.

Math is simple, but there still needs a few details to be clarified.  Last November 51 patients had been treated in PH2 plus they were counting the 3 from PH1 for a total of  54.  Now they have not mentioned 3 from PH1 and are simply stating that 57 patients have been treated in PH2.  Plus they are removing patient  that died, so a total of 56 patients ( includes 12 undertreated patients). Swimmers plot includes 12 under treated at 90 days, but not going forward. Chart also shows how 12 are included in evaluable patients at 90 days , but not going forward at other time points.  They are still others probably for safety evaluation, but will be removed eventually completely.  IMO 
<< Previous
Bullboard Posts
Next >>